BACKGROUND: The resistance to antimicrobial agents among Staphylococci is an increasing problem. This has led to a renewed interest in the usage of macrolide-lincosamide-streptogramin B (MLSB) antibiotics to treat staphylococcal infections. Clinical failure has been reported due to multiple mechanisms that confer resistance to clindamycin antibiotics. The present study was to investigate the inducible clindamycin resistance among isolates of methicillin resistant Staphylococci by the D-test method.
INTRODUCTION

Coagulase-Positive
Staphylococci (CPS) and coagulase-negative Staphylococci (CNS) are recognized as important pathogens that cause nosocomial and community acquired infections in every region of the world. The rising prevalence of methicillin resistance 
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among Staphylococci is an escalating problem [1] , which has renewed the attention for using other effective drugs to treat staphylococcal infections, such as the (MLSB) antibiotics, which act through the common mechanism of protein synthesis inhibition, and are widely used to treat such infections [2] . Clindamycin (a lincosamide) is the agent preferred by clinicians due to its excellent pharmacokinetic properties [3] . The wide spread use of the MLSB family of antimicrobials has led to the emergence of resistance to this group of antibiotics [4] .
The macrolide antibiotic resistance in Staphylococci can be mediated by the macrolide streptogramin (msr) A gene (MS phenotype) which codes for an efflux mechanism that confer resistance to the macrolides and the type B streptogramin only, which has been more prevalent in CNS than in S. aureus or via the erythromycin ribosome methylase (erm) gene designated the MLSB phenotype [4] . The expression of the MLSB phenotype may be constitutive (cMLSB) or inducible (iMLSB) [5] . Patients infected with iMLSB strains of Staphylococci if treated with clindamycin can develop resistance during therapy resulting in treatment failure [6] . The MS and iMLSB phenotypes are indistinguishable by using standard susceptibility test methods. For the iMLSB strains, erythromycin will induce production of the methylase, which allows clindamycin resistance to be expressed [7] . This inducible clindamycin resistance can be detected with an erythromycin-clindamycin simple disk approximation test, commonly referred to as D-test as described by Fiebelkorn et al. [7] .
PATIENTS & METHODS
This prospective study was conducted on (218) nonrepeating isolates of Staphylococci obtained from various clinical specimens (pus swabs, drains, blood cultures, urine, sputum, vagina swabs, nasal swabs, ear swabs, ear swabs, throat swabs and urethral discharge) of outpatients visiting and inpatients admitted to Tripoli Central Hospital (TCH), Libya during the period from June 2013 to June 2014. The isolates were fully identified by standard conventional laboratory methods. MRSA and MRCNS isolates were initially identified using oxacillin (1 μg) and cefoxitin (30 μg) disks (Oxoid -UK). An inhibition zone of ≤ 10 mm around oxacillin disk indicates methicillin resistance. In regard to cefoxitin disk, an inhibition zone of ≤ 21 mm was considered as methicillin resistant in accordance to Clinical and Laboratory Standards Institute (CLSI) guidelines [8] . In addition, the methicillin resistant isolates were subjected to chromogenic MRSA media (BioMerieux-France) and oxacillin screening media supplemented with 4% NaCl and oxacillin (6 μg/ml) (Becton Dickinson BDBBL).
For the detection of inducible clindamycin resistance, each isolate showed which was resistant to erythromycin was subjected to D-test by placing erythromycin (15μg) and clindamycin (2 μg) disc on Mueller-Hinton agar (BioMe´rieux, France) at adjacent positions, 15mm apart. Isolates resistant to erythromycin and having a clindamycin zone ≥ 21 mm with a flattened D-shaped zone in the area between the two discs were regarded as positive test for inducible resistance (iMLSB phenotype) [7, 8] . Isolates exhibiting resistance to erythromycin but sensitive to clindamycin, giving circular zone of inhibition, were considered negative for D-test (MS phenotype),‫؛‬ meanwhile, those staphylococcal isolates resistant to both erythromycin and clindamycin were regarded as constitutively resistant (cMLSB phenotypes). Isolates sensitive to both erythromycin and clindamycin were regarded as susceptible strains.
Staphylococcus aureus ATCC 25923 was used as the control strain.
STATISTICAL ANALYSIS
Statistical analysis of the results were presented as frequencies and percentages using Microsoft Excel 2003 (version 11, Microsoft Corporation WA, USA).
RESULTS
The majority of the isolates were obtained from pus swabs 174/218 (79.8%), followed by blood cultures 13 (6.0%), drain samples 9 (4.1%) and ear swabs 8 (3.7%). 
DISCUSSION
Resistance to the majority of antibiotics used in the treatment of staphylococcal infections is an escalating problem [9] . The changing pattern in antibiotic susceptibility has led to a renewed interest in the use of clindamycin [1] . Clindamycin has been frequently used to treat skin and bone infections caused by staphylococcal species because of its low cost, good oral absorption and excellent tissue penetration making this drug an important option in outpatient therapy and change over after intravenous therapy. It is also used as an alternative in penicillin-allergic patients [7, 10] . Therapeutic failures caused by iMLSB resistant strains are now being commonly reported. Routine antimicrobial sensitivity testing can detect cMLSB phenotypes but iMLSB resistance is missed if erythromycin and clindamycin discs are placed at nonadjacent sites [7, 11] . In our study we found that the prevalence of erythromycin-resistant staphylococcal isolates was 39.4% (86/218) which is slightly lower than that reported by previous local study (46%) [12] and a regional study(52.2%) [13] .
In the present study, the prevalence of iMLSB, cMLSB and MS resistance phenotype was 11.9%, 11.0% and 16.5% respectively. These findings are quite similar to those of Zorgani et al. [12] who found that in Tripoli, 27% of staphylococcal isolates were of the iMLSB phenotype whilst 3.2% and 15.1%exhibited the cMLSB and MS phenotypes respectively. Another recent study from Benghazi, reported that 4.5% of staphylococcal isolates had the iMLSB phenotype and 7.1 % were constitutively resistant and the MS phenotype constituted only 2.7% of the isolates [14] . Researchers from Egypt reported that the percentages of iMLSB, cMLSB and MS resistance phenotypes were 7.7%, 6.6 % and 37.7 % respectively [13] . Such differences in the MLSB-resistance pattern could be caused by differences in guidelines for drug usage in each country and is likely to vary by region. Various studies have shown the prevalence of the cMLSB phenotype to range from 11 to 27% and the MSB phenotype from 12 to 44% [15] . In the present study, infections caused by the MS phenotype isolates (16.5%), were treatable with clindamycin without fearing the emergence of resistance during therapy. But (11.9%) of patients infected with iMLSB strains if treated with clindamycin might develop resistance during therapy resulting in treatment failure.
A comparison of the prevalence rates of iMLSB isolates within the methicillin-susceptible staphylococci in different studies is displayed in 
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Our study shows that the prevalence rates of iMLSB among methicillin resistant strains were higher (19.4% for MRSA and 17.0% for MRCNS) than in methicillin sensitive isolates (6.4% in MSSA and 0% in MSCNS). This finding is concordant with those reported by most other studies [1, 12, 13, 14, 16, 17, 18] where the iMLSB was also found to be more common among the methicillin resistant staphylococcal isolates. It is clearly evident from these studies that the incidence of clindamycin resistance and the MLSB phenotypes varies significantly between clinical isolates from different geographical regions [1, 12, 13, 14, 16, 17, 18] (Table 2 ). 
CONCLUSION
There is a high prevalence of inducible clindamycin resistance (iMLSB) phenotype in methicillin-resistant compared with methicillin-sensitive isolates. The D-test is an easy, sensitive, and reliable means for detection of iMLSB strains in a clinical laboratory setting without specialized testing facilities. D-test reporting should continue to be done routinely for staphylococcal infections in order to reduce morbidity and mortality associated with inadvertent delay in administering the appropriate antibiotic treatment for these potentially serious maladies. 
